AXOVANT GENE THERAPIES LTD - COM (AXGT)

CUSIP: G0750W203

Q2 2019 13F Holders as of 30 Jun 2019

Type / Class
Equity / COM
Total 13F shares
3,069,757
Share change
+2,834,684
Total reported value
$19,124,480
Put/Call ratio
99%
Price per share
$6.23
Number of holders
32
Value change
+$18,720,995
Number of buys
30
Number of sells
2

Quarterly Holders Quick Answers

What is CUSIP G0750W203?
CUSIP G0750W203 identifies AXGT - AXOVANT GENE THERAPIES LTD - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of AXOVANT GENE THERAPIES LTD - COM (AXGT) as of Q2 2019

As of 30 Jun 2019, AXOVANT GENE THERAPIES LTD - COM (AXGT) was held by 32 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,069,757 shares. The largest 10 holders included SPHERA FUNDS MANAGEMENT LTD., CITADEL ADVISORS LLC, Hudson Bay Capital Management LP, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., PRIMECAP MANAGEMENT CO/CA/, CREDIT SUISSE AG/, BANK OF AMERICA CORP /DE/, and JANE STREET GROUP, LLC. This page lists 32 institutional shareholders reporting positions in this security for the Q2 2019 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.